

Pavel Gershkovich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8682322/publications.pdf>

Version: 2024-02-01

90
papers

2,256
citations

230014

27
h-index

286692

43
g-index

92
all docs

92
docs citations

92
times ranked

2985
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers. <i>Pharmaceutics</i> , 2022, 14, 270.	2.0	5
2	Is oral lipid-based delivery for drug targeting to the brain feasible?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 112-122.	2.0	8
3	Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 174, 29-34.	2.0	10
4	Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121947.	2.6	7
5	Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. <i>Journal of Controlled Release</i> , 2021, 329, 1077-1089.	4.8	25
6	Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate. <i>Molecules</i> , 2021, 26, 233.	1.7	0
7	Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus. <i>Viruses</i> , 2021, 13, 234.	1.5	33
8	Development and optimisation of simulated salivary fluid for biorelevant oral cavity dissolution. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 160, 125-133.	2.0	10
9	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113244.	2.6	10
10	Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 162, 43-49.	2.0	19
11	Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120621.	2.6	8
12	Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 35266-35280.	4.0	15
13	Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. <i>Pharmaceutics</i> , 2021, 13, 1349.	2.0	9
14	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 106-112.	2.0	0
15	Assessing Lymphatic Uptake of Lipids Using Magnetic Resonance Imaging: A Feasibility Study in Healthy Human Volunteers with Potential Application for Tracking Lymph Node Delivery of Drugs and Formulation Excipients. <i>Pharmaceutics</i> , 2021, 13, 1343.	2.0	0
16	Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin. <i>Virulence</i> , 2021, 12, 2946-2956.	1.8	12
17	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 316-321.	1.3	3
18	Is rat a good model for assessment of particulate-based taste-masked formulations?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 146, 1-9.	2.0	5

#	ARTICLE	IF	CITATIONS
19	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1493-1500.	1.6	31
20	Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 7283.	1.3	5
21	Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4934.	0.8	6
22	Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 12609-12617.	4.0	24
23	Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. <i>Journal of Controlled Release</i> , 2020, 323, 549-564.	4.8	13
24	Abstract 1727: Challenging resistance to temozolomide in glioblastoma by drug encapsulation in apoferritin. , 2020, , .		0
25	Targeting brain tumours: apoferritin nanocage for delivery of novel analogues of temozolomide. <i>Neuro-Oncology</i> , 2019, 21, iv4-iv4.	0.6	1
26	A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin. <i>Scientific Reports</i> , 2019, 9, 15760.	1.6	17
27	Solid lipid nanoparticles self-assembled from spray dried microparticles. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118784.	2.6	8
28	Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition. <i>Cancer Letters</i> , 2019, 453, 57-73.	3.2	37
29	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 65-71.	1.1	1
30	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine. <i>International Journal of Pharmaceutics</i> , 2019, 555, 228-236.	2.6	15
31	Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1047-1052.	1.6	7
32	In search of effective therapies to overcome resistance to Temozolomide in brain tumours. , 2019, 2, 1018-1031.		7
33	Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation. <i>Molecular Pharmaceutics</i> , 2018, 15, 1578-1586.	2.3	3
34	Analytical ultracentrifugation in saliva research: Impact of green tea astringency and its significance on the in-vivo aroma release. <i>Scientific Reports</i> , 2018, 8, 13350.	1.6	8
35	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. <i>Journal of Controlled Release</i> , 2018, 286, 10-19.	4.8	41
36	Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 114, 38-42.	2.0	61

#	ARTICLE	IF	CITATIONS
37	Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 100, 163-175.	1.9	7
38	Development of Cordycepin Formulations for Preclinical and Clinical Studies. <i>AAPS PharmSciTech</i> , 2017, 18, 3219-3226.	1.5	16
39	Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. <i>Scientific Reports</i> , 2017, 7, 14542.	1.6	93
40	Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1040, 73-80.	1.2	16
41	Targeting Immunomodulatory Agents to the Gut-Associated Lymphoid Tissue. , 2016, , 237-261.		5
42	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 659-664.	0.6	8
43	Linking <i>in Vitro</i> Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations. <i>Molecular Pharmaceutics</i> , 2016, 13, 3526-3540.	2.3	14
44	The role of acid-base imbalance in statin-induced myotoxicity. <i>Translational Research</i> , 2016, 174, 140-160.e14.	2.2	28
45	Smart Lipid-Based Drug Delivery Systems. , 2016, , 309-371.		2
46	In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B. <i>Cancer Letters</i> , 2016, 370, 185-197.	3.2	41
47	Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 3448-59.	0.0	47
48	Lipid-lowering Activity of Natural and Semi-Synthetic Sterols and Stanols. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 344.	0.9	24
49	Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and δ^9 -tetrahydrocannabinol in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 145-151.	1.4	56
50	Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 353-362.	2.0	56
51	Characterisation of human saliva as a platform for oral dissolution medium development. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 91, 16-24.	2.0	108
52	Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 1425-1430.	0.9	9
53	Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. <i>Drugs in Context</i> , 2015, 4, 1-6.	1.0	7
54	Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. <i>Translational Research</i> , 2014, 164, 85-109.	2.2	46

#	ARTICLE	IF	CITATIONS
55	Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. <i>Pharmaceutical Research</i> , 2014, 31, 35-45.	1.7	37
56	Dissolution methodology for taste masked oral dosage forms. <i>Journal of Controlled Release</i> , 2014, 173, 32-42.	4.8	64
57	The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 1429-1434.	0.9	18
58	A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 338-344.	0.9	15
59	Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1277-1283.	0.9	16
60	Evaluation of the effect of plant sterols on the intestinal processing of cholesterol using an in vitro lipolysis model. <i>International Journal of Pharmaceutics</i> , 2012, 436, 707-710.	2.6	7
61	Inhibition of Cholesterol Absorption: Targeting the Intestine. <i>Pharmaceutical Research</i> , 2012, 29, 3235-3250.	1.7	15
62	Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. <i>International Journal of Pharmaceutics</i> , 2012, 436, 318-323.	2.6	11
63	Long-circulating non-toxic blood pool imaging agent based on hyperbranched polyglycerols. <i>International Journal of Pharmaceutics</i> , 2012, 422, 418-427.	2.6	38
64	Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 323-328.	1.9	26
65	Assessment of Cholesterol Absorption Inhibitors Nanostructured Aluminosilicate and Cholestyramine Using In Vitro Lipolysis Model. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 291-300.	1.6	13
66	Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 36.	0.9	4
67	Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data. <i>AAPS Journal</i> , 2011, 13, 255-64.	2.2	23
68	Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. <i>Lipids in Health and Disease</i> , 2011, 10, 135.	1.2	26
69	In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against <i>Candida albicans</i> , human monocytic and kidney cell lines. <i>Lipids in Health and Disease</i> , 2011, 10, 144.	1.2	12
70	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 513-523.	1.4	32
71	The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 31-39.	1.2	32
72	Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2610-2613.	1.3	28

#	ARTICLE	IF	CITATIONS
73	Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 535-537.	1.3	20
74	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 599-599.	1.3	0
75	A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e913.	1.3	51
76	Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and norclozapine following administration to rats. <i>European Neuropsychopharmacology</i> , 2010, 20, 545-552.	0.3	9
77	Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2390-2400.	1.6	23
78	Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with <i>Aspergillus fumigatus</i> or <i>Candida albicans</i> . <i>International Journal of Pharmaceutics</i> , 2009, 372, 76-84.	2.6	105
79	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 101-108.	1.3	76
80	Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. <i>Translational Research</i> , 2009, 153, 296-300.	2.2	4
81	Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet. <i>Lipids in Health and Disease</i> , 2009, 8, 30.	1.2	14
82	Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2009, 200, 357-360.	1.9	79
83	The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 31-39.	1.2	10
84	A Review of the Application of Lipid-Based Systems in Systemic, Dermal/ Transdermal, and Ocular Drug Delivery. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2008, 25, 545-584.	1.2	49
85	The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 67, 759-765.	2.0	89
86	Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2007, 1771, 839-844.	1.2	7
87	The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. <i>International Journal of Pharmaceutics</i> , 2007, 333, 1-4.	2.6	19
88	Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: Dexanabinol and PRS-211,220. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 31, 298-305.	1.9	42
89	Effect of a high-fat meal on absorption and disposition of lipophilic compounds: The importance of degree of association with triglyceride-rich lipoproteins. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 32, 24-32.	1.9	78
90	Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 394-404.	1.9	116